SOPACHEM : LIFE SCIENCES - BIOBANKING - DIAGNOSTICS - ANALYTICAL

Lp-PLA2 – Marker for the Atherosclerotic Risk Assessment

Product Type: , ,

LP-PLA2

Clinical Relevance of Lp-PLA2

Lp-PLA2 (Lipoprotein-associated phospholipase A2) – also known as platelet-activating factor acetylhydrolase (PAF-AH) – is a vascular-specifc inflammatory enzyme, predominantly expressed by macrophages, lymphocytes and foam cells in atherosclerotic plaques. Circulating Lp-PLA2 is mainly associated with apolipoprotein B-containing lipoproteins, hence closely associated with low-density lipoprotein (LDL). The enzyme hydrolyzes oxidized phospholipids on LDL particles within the arterial intima, generating two highly inflammatory mediators, lysophosphatidylcholine (Lyso-PC) and oxidized non-esterified fatty acids (oxNEFAs).

Many important studies confirm a strong association between Lp-PLA2 levels and cardiovascular risk among different populations. These studies show that in individuals with normal LDL, elevated Lp-PLA2 levels were strongly associated with heart disease and ischemic stroke, independent of traditional risk markers and high-sensitive CRP. Due to the fact that Lp-PLA2 is involved in the causal pathway of plaque inflammation and plaque rupture, the testing for Lp-PLA2 represents a valuable adjunctive tool which goes beyond traditional cardiovascular risk assessment.

The Importance of Lp-PLA2 Testing

It is well known, that inflammatory processes play an important role in the pathogenesis of atherosclerosis. Established risk factors account for part of the cardiovascular diseases only. Lp-PLA2, a new reliable marker in the atherosclerotic risk assessment, is able to close this diagnostic gap.

Studies provide strong evidence, that the presence of Lp-PLA2 is associated with an increased risk of cardiac death, myocardial infarction, acute coronary syndrome and ischemic stroke. Increased Lp-PLA2 concentrations can be found in vulnerable atherosclerotic plaques and allow discrimination between morphologically identical stable and unstable plaques. Lp-PLA2 testing is an excellent complement to angiography because it detects very small plaques not visible by medical imaging. Unlike traditional atherosclerotic risk markers Lp-PLA2 is highly specifc for vascular inflammation, has low biological variability, and plays a causative role in atherosclerotic plaque inflammation.

 

  • ↓ Diasys LpPLA2 Brochure

  • Caslake MJ et al 2000. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis:150(2): 413-419.

    Stafforini DM et al 1999. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem;274:7018-24.

    Wilensky RL et al 2008. Inhibition of Lipoprotein-associated phospholipase A2 reduces complexcoronary atherosclerotic plaque development. Nat Med;14:1059-66.

    Vickers KC et al 2009. Relationship of Lipoprotein-Associated Phospholipase A2 and Oxidited Low-Density Lipoprotein in Carotid Atherosclerosis. JLR;50(9):1735-44.

    Zalewski A and Macphee C 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol;25:923-31.

    Caslake MJ and  Packard CJ 2003. Lipoprotein-Associated Phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol;14:347-52.

    Packard CJ et al 2000. Lipoprotein-Associated Phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med;343:1148-55.

    Garza CA et al 2007. Lipoprotein-Associated Phospholipase A2 and cardiovascular disease: a systemic review. Association between Mayo Clin Proc;82:159-65.

    Kaminsky LA and Ozmek C 2012.Diurnal variation in lipoprotein-associated phospholipase A2 (Lp-PLA2). Clin Biochem;45(9):700-702.

     

    Atherosclerotic Plaques and Lp-PLA2

    Kolodgie FD et al 2006. Lipoprotein-Associated Phospholipase A2 expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol;26:2523-29.

    Mannheim D et al 2008. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques.
    Stroke;39:1448-55.

    Frank D et al 2006. Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol;26:2523-2529.

     

    Lp-PLA2 Studies

    The Lp-PLA2 Studies Collaboration: Lipoprotein-Associated Phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44. Biol;27:1788-1795.

    The Lp-PLA2 Studies Colaboration. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007;14:3-11.

    Caslake MJ et al. 2010. Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis;210(1):28-34.

    Kiechl S et al 2007. Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study. Arterioscler Thromb Vasc Biol;27:1788-1795.

    Moeckel M et al. 2007 – The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Lipoprotein-associated phopolipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach. Clin Res Cardiol 96:1-9.

     

    Lp-PLA2 – Mass vs Activity

    Persson M et al 2007. Elevated Lp-PLA2 Levels Add Prognostic Information of the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabteic Subjects. Arterioscler Thromb Vasc Biol;27:1411-1416.

    O’Donoghue M et al 2006. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation;113(14):1745-52.

     

    Racial Variation

    Lee KK et al 2011. Racial variation in lipoprotein-associated phospholipase A2 in older adults. BMC Cardiovascular Disorders;11:38.

    Brilakis ES et al 2008. Influence of Race and Sex on Lipoprotein-Associated Phospholipase A2 Levels: Observations from the Dallas Heart Study. Atherosclerosis;199(1):110-115.

    Hoffmann MM et al 2009. Genetic variants and haplotypes of  Lipoprotein-associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascukar Helath Study). J Thromb Haemost;7:41-48.

     

    Therapeutic Action Studies – Effects on Lp-PLA2

    Muhlestein JB et al 2006. The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. J Am CollCardiol;48:396-401.

    Winkler K et al 2004. Fluvastatin Slow-Release Lowers Platelet-Activating Factor Acetyl Hydrolase Activity: A Placebo-Controlled Trial in Patients with Type 2 Diabetes. J Clin Endocrinol Metab;89:1153-1159.

    Albert MA et al 2005. The Effectof Statin Therapy on Lipoprotein Associated Phospholipase A2 Levels. Atherosclerosis;182:193-198.

    Schaefer EJ et al 2005. Effects of Atorvastatin Versus Other Statins on Fasting and Postprandial C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Patients With CoronaryHeart Disease Versus Control Subjects. Am J Cardiol;95:1025-1032.

    Vasilios G et al 2007. Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2.  Arterioscler Throm Vasc Biol;27:2236-2243.

  • Visit the Lp-PLA2 Microsite

Related Portfolio

Evalution multiplex analysis platform for biomarkers

Aspect Plus – ST2 Quantitative Rapid Test

Presage® ST2 – Heart Failure Prognosis

request a sample / demo

request a quote

Diasys Product Catalogue

Diasys catalog 2016 cover picture

Supplier

OUR MOTIVATION

Many established technology providers learned the hard way that having a worldwide direct sales force, is often not the best solution. Now that the focus might have shifted to other continents, the cost of local affiliates weigh heavily on their organizations. For new and upcoming players, the investments are too high and the local barriers too complex. For innovative suppliers in general, the typical resellers and large catalog companies will lack the scientific knowhow and focus in order to be successful. New innovative suppliers need to have a fast and efficient access to the world. As the Life Science part of the Aptco Invest group of companies, the Sopachem team tries hard to redefine the meaning of the word 'distributor'.

OUR VISION

A local partner willing to go the extra mile, can offer the best of both worlds. We envisioned that by delivering more than what is expected of a distributor, it is possible to become a true local sales and marketing partner for our suppliers. With sales and service engineers trained to the same level of a direct sales force, both the customers and suppliers win. For our instrumentation suppliers, a strong service team is an essential driver for success. For reagents and consumables, we can ensure next-day deliveries to our endusers thanks to our centralized operations with local stock.

OUR MISSION

Serving laboratories in the Benelux, Sopachem thrive to be such kind of distributor. To maintain our focus, we created several divisions, each serving their specific markets, each with team of high level product and application specialist behind them. For our suppliers, our mission is to be the best sales and marketing partner available in our region, bringing the word distributor to another level. For our customers, it is our mission to serve them with highest standards of product knowhow, understanding their needs and applications. Be it by offering the best service or by introducing innovative technologies that will in the end help them advance their scientific work.
Privacy Policy - design by Get Graphics - Google+